A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT

Alpha Tau Medical

Status: Completed

Conditions: Squamous Cell Carcinoma; DaRT Treated Patients

Study type: Observational

Funder types: Industry

Identifiers

NCT05125354

CTP-SCC-02

Details and patient eligibility

About

Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.

Full description

Medical records of patients that previously underwent the Alpha DaRT treatment will be reviewed by an authorized staff member.

Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include:

• Safety - assessment of late onset of Alpha DaRT related AE in patients treated with the Alpha DaRT seeds

• Efficacy -

  • assessment of local recurrence rates in patients who achieved initial complete response (CR) following the Alpha DaRT treatment
  • assessment of duration of response in patients who achieved initial CR following the Alpha DaRT treatment
  • assessment of survival status in patients treated with the Alpha DaRT seeds

Enrollment: 33 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients previously treated with the Alpha DaRT seeds for management of either skin or oral cavity SCC
• Available information in medical charts and records (electronic or paper)

Exclusion criteria

None.